SG11201700734RA - Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them - Google Patents
Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing themInfo
- Publication number
- SG11201700734RA SG11201700734RA SG11201700734RA SG11201700734RA SG11201700734RA SG 11201700734R A SG11201700734R A SG 11201700734RA SG 11201700734R A SG11201700734R A SG 11201700734RA SG 11201700734R A SG11201700734R A SG 11201700734RA SG 11201700734R A SG11201700734R A SG 11201700734RA
- Authority
- SG
- Singapore
- Prior art keywords
- methyl
- tetrahydroquinoline
- triazol
- fluorophenyl
- carboxylate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B57/00—Separation of optically-active compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/19—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462031521P | 2014-07-31 | 2014-07-31 | |
| PCT/US2015/042867 WO2016019125A1 (fr) | 2014-07-31 | 2015-07-30 | Sels conformères de 7-fluoro-2-(4-fluorophényl)-3-(1-méthyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tétrahydroquinoléine-5-carboxylate de (2s,3s)-méthyle et leurs procédés de préparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201700734RA true SG11201700734RA (en) | 2017-02-27 |
Family
ID=55218310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201700734RA SG11201700734RA (en) | 2014-07-31 | 2015-07-30 | Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20170217921A1 (fr) |
| EP (1) | EP3174855B1 (fr) |
| JP (3) | JP2017523243A (fr) |
| KR (1) | KR20170038850A (fr) |
| CN (1) | CN107155326B (fr) |
| AU (1) | AU2015296289B2 (fr) |
| BR (1) | BR112017001977A2 (fr) |
| CA (1) | CA2956714A1 (fr) |
| EA (1) | EA201790290A1 (fr) |
| ES (1) | ES2947501T3 (fr) |
| IL (1) | IL250365B (fr) |
| MX (1) | MX2017001416A (fr) |
| SG (1) | SG11201700734RA (fr) |
| TW (1) | TWI693214B (fr) |
| WO (1) | WO2016019125A1 (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8012976B2 (en) | 2008-08-06 | 2011-09-06 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
| AU2011212928B2 (en) | 2010-02-03 | 2016-06-23 | Medivation Technologies Llc | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose) polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency |
| WO2011097602A1 (fr) | 2010-02-08 | 2011-08-11 | Biomarin Pharmaceutical Inc. | Procédés de synthèse de dérivés de dihydropyridophtalazinone |
| SG189939A1 (en) | 2010-10-21 | 2013-06-28 | Biomarin Pharm Inc | Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt |
| US9708319B1 (en) * | 2016-06-13 | 2017-07-18 | Yong Xu | Synthesis of PARP inhibitor talazoparib |
| BR112020006371A2 (pt) | 2017-10-13 | 2020-09-29 | Merck Patent Gmbh | combinação de um inibidor de parp e um antagonista de ligação de eixo de pd-1 |
| TW201938165A (zh) | 2017-12-18 | 2019-10-01 | 美商輝瑞股份有限公司 | 治療癌症的方法及組合療法 |
| EP3876940A1 (fr) | 2018-11-05 | 2021-09-15 | Pfizer Inc. | Combinaisons pour le traitement du cancer |
| EP4118105A2 (fr) | 2020-03-09 | 2023-01-18 | Pfizer Inc. | Protéines de fusion et leurs utilisations |
| EP4243785A1 (fr) | 2020-11-13 | 2023-09-20 | Pfizer Inc. | Forme galénique de capsule de gélatine molle de talazoparib |
| WO2022123427A1 (fr) | 2020-12-07 | 2022-06-16 | Pfizer Inc. | Procédés d'identification d'une tumeur sensible au traitement par le talazoparib et procédés de traitement associés |
| JP2024510666A (ja) | 2021-03-24 | 2024-03-08 | ファイザー・インク | Ｄｄｒ遺伝子変異転移性去勢感受性前立腺がんを処置するためのタラゾパリブおよび抗アンドロゲンの組合せ |
| WO2023131894A1 (fr) | 2022-01-08 | 2023-07-13 | Pfizer Inc. | Perte d'hétérozygotie génomique en tant que biomarqueur prédictif pour le traitement par le talazoparib et méthodes de traitement de cette perte d'hétérozygotie génomique |
| WO2024074959A1 (fr) | 2022-10-02 | 2024-04-11 | Pfizer Inc. | Combinaison de talazoparib et d'enzalutamide dans le traitement du cancer de la prostate résistant à la castration métastatique |
| WO2024127140A1 (fr) | 2022-12-17 | 2024-06-20 | Pfizer Inc. | Combinaison de talazoparib et d'enzalutamide dans le traitement du cancer de la prostate résistant à la castration et métastatique |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4415504A (en) * | 1981-09-21 | 1983-11-15 | Tanabe Seiyaku Co., Ltd. | p-Hydroxyphenylglycine.α-phenylethanesulfonate, process for production thereof and utilization thereof in resolution of p-hydroxyphenylglycine |
| JPS5852253A (ja) * | 1981-09-21 | 1983-03-28 | Tanabe Seiyaku Co Ltd | Ρ−ヒドロキシフエニルグリシン・α−フエニルエタンスルホン酸塩及びその光学分割法 |
| JPS63192753A (ja) * | 1987-02-05 | 1988-08-10 | Otsuka Pharmaceut Co Ltd | テトラヒドロキノリン誘導体の光学分割法 |
| JPH08322591A (ja) * | 1995-06-02 | 1996-12-10 | Sumitomo Pharmaceut Co Ltd | 光学分割により光学的に純粋な１，２，３，４−テトラヒドロキノリン−２−酢酸エステル類を得る方法 |
| JP2010536807A (ja) * | 2007-08-22 | 2010-12-02 | ４エスツェー アクチェンゲゼルシャフト | キネシンスピンドルタンパク質（ｅｇ５）の阻害剤としてのインドロピリジン |
| CN101298452A (zh) * | 2008-06-30 | 2008-11-05 | 南京华威医药科技开发有限公司 | S-(-)-那氟沙星及其水溶性盐的制备方法和用途 |
| US8012976B2 (en) * | 2008-08-06 | 2011-09-06 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
| BRPI0914556A2 (pt) * | 2008-08-12 | 2015-08-04 | Boehringer Ingelheim Int | Processo para a preparação de compostos de piperazina substituídos por cicloalquila |
| WO2011097602A1 (fr) | 2010-02-08 | 2011-08-11 | Biomarin Pharmaceutical Inc. | Procédés de synthèse de dérivés de dihydropyridophtalazinone |
| SG189939A1 (en) * | 2010-10-21 | 2013-06-28 | Biomarin Pharm Inc | Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt |
| WO2013028495A1 (fr) * | 2011-08-19 | 2013-02-28 | Biomarin Pharmaceutical Inc. | Inhibiteurs dihydropyridophthalazinone de poly (adp-ribose) polymérase (parp) pour le traitement du myélome multiple |
-
2015
- 2015-07-30 EP EP15826816.9A patent/EP3174855B1/fr active Active
- 2015-07-30 EA EA201790290A patent/EA201790290A1/ru unknown
- 2015-07-30 ES ES15826816T patent/ES2947501T3/es active Active
- 2015-07-30 CA CA2956714A patent/CA2956714A1/fr not_active Abandoned
- 2015-07-30 CN CN201580052825.0A patent/CN107155326B/zh active Active
- 2015-07-30 US US15/329,549 patent/US20170217921A1/en not_active Abandoned
- 2015-07-30 WO PCT/US2015/042867 patent/WO2016019125A1/fr active Application Filing
- 2015-07-30 JP JP2017526474A patent/JP2017523243A/ja not_active Withdrawn
- 2015-07-30 SG SG11201700734RA patent/SG11201700734RA/en unknown
- 2015-07-30 KR KR1020177004847A patent/KR20170038850A/ko active IP Right Grant
- 2015-07-30 MX MX2017001416A patent/MX2017001416A/es unknown
- 2015-07-30 BR BR112017001977A patent/BR112017001977A2/pt not_active Application Discontinuation
- 2015-07-30 AU AU2015296289A patent/AU2015296289B2/en active Active
- 2015-07-31 TW TW104124989A patent/TWI693214B/zh active
-
2017
- 2017-01-30 IL IL250365A patent/IL250365B/en active IP Right Grant
-
2018
- 2018-09-11 US US16/128,406 patent/US20190106401A1/en not_active Abandoned
-
2020
- 2020-04-02 JP JP2020067069A patent/JP2020125303A/ja not_active Withdrawn
- 2020-08-10 US US16/989,841 patent/US20210094930A1/en not_active Abandoned
-
2022
- 2022-06-03 JP JP2022090681A patent/JP2022116288A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| TW201617319A (zh) | 2016-05-16 |
| EA201790290A1 (ru) | 2017-07-31 |
| JP2017523243A (ja) | 2017-08-17 |
| JP2022116288A (ja) | 2022-08-09 |
| IL250365B (en) | 2021-02-28 |
| AU2015296289A1 (en) | 2017-03-02 |
| BR112017001977A2 (pt) | 2017-11-21 |
| TWI693214B (zh) | 2020-05-11 |
| US20190106401A1 (en) | 2019-04-11 |
| NZ728634A (en) | 2021-09-24 |
| JP2020125303A (ja) | 2020-08-20 |
| EP3174855A1 (fr) | 2017-06-07 |
| US20170217921A1 (en) | 2017-08-03 |
| ES2947501T3 (es) | 2023-08-10 |
| MX2017001416A (es) | 2017-05-19 |
| KR20170038850A (ko) | 2017-04-07 |
| IL250365A0 (en) | 2017-03-30 |
| US20210094930A1 (en) | 2021-04-01 |
| CA2956714A1 (fr) | 2016-02-04 |
| WO2016019125A1 (fr) | 2016-02-04 |
| CN107155326A (zh) | 2017-09-12 |
| EP3174855A4 (fr) | 2018-03-21 |
| CN107155326B (zh) | 2021-03-05 |
| AU2015296289B2 (en) | 2020-02-27 |
| EP3174855B1 (fr) | 2023-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL250365A0 (en) | Coformer salts of (2s, 3s)-methyl-7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1, 2, 4-triazol-5-yl)-4-oxo-1, 2, 3, 4-tetrahydroquinoline-5 carboxylate and methods for their preparation | |
| PT3546457T (pt) | Derivado de pirazolo-heteroarílico, método de preparação e a utilização médica do mesmo | |
| HK1231377A1 (zh) | 包含喹啉衍生物或其鹽的藥物組合物及其製備方法 | |
| HK1251551A1 (zh) | 氮雜環丁烷衍生物、其製備方法及用途 | |
| IL289099A (en) | Methods for storage of whole blood, and corresponding preparations | |
| EP3286996A4 (fr) | Machine powder ridge de sous-solage de type étendu et machine powder ridge de sous-solage | |
| IL247833B (en) | 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-converted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation | |
| IL247832A0 (en) | 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-converted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation | |
| IL247593A0 (en) | Surgical robotic system and method for surgical planning and implant preparation | |
| HUE059672T2 (hu) | Kinolinvegyületek, eljárás azok elõállítására, és urát transzporter inhibitor gyógyzserként történõ alkalmazásuk | |
| EP3115361A4 (fr) | Composés hétérocycliques et leur méthode de préparation et d'utilisation | |
| EP3109240A4 (fr) | Composé de triazine et son utilisation à des fins médicales | |
| PT3527552T (pt) | Derivado fundido tricíclico de -aminoácido, seu método de preparação, e sua utilização médica | |
| SG11201709414XA (en) | Powdered titanium oxide, method for the production thereof, and use thereof | |
| EP3261580A4 (fr) | Système d'identification d'un plan dentaire | |
| HK1250662A1 (zh) | 用於治療癌症的免疫原性融合蛋白 | |
| SI3331583T1 (sl) | Medicinski implantat na osnovi nanoceluloze | |
| EP3556761A4 (fr) | Composé hétérocyclique pyrrolo-aromatique, son procédé de préparation et son utilisation médicale | |
| EP3171840A4 (fr) | Implant médical amélioré | |
| HRP20200104T8 (hr) | Novi heterociklični spoj, metoda za pripremu istog, i farmaceutska kompozicija koja sadrži isto | |
| EP3118244A4 (fr) | Nouveau composé polyphosphazène cationique, composé conjugué polyphosphazènes-médicament, et son procédé de préparation | |
| MX369506B (es) | Composiciones de sales metálicas. | |
| GB201714060D0 (en) | Method for preparing itraconazole preparation | |
| EP3199526A4 (fr) | Intermédiaire utile dans la synthèse de la paroxétine, procédé de préparation de l'intermédiaire et utilisations associées | |
| EP3231455A4 (fr) | Composition biocompatible et son procédé de préparation |